These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G; Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of remitting forms of multiple sclerosis]. Lubetzki C Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):996-1000. PubMed ID: 11787366 [TBL] [Abstract][Full Text] [Related]
7. Discontinuing Treatment Against Medical Advice: The Role of Perceived Autonomy Support From Providers in Relapsing-Remitting Multiple Sclerosis. Glusman M; Bruce A; Thelen J; Smith J; Lynch S; Catley D; Bennett KK; Bruce J Ann Behav Med; 2019 Mar; 53(3):283-289. PubMed ID: 29771271 [TBL] [Abstract][Full Text] [Related]
9. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802 [TBL] [Abstract][Full Text] [Related]
10. Quality of life in patients with multiple sclerosis and their caregivers in Colombia: One-year follow-up. Beltrán E; Díaz D; Díaz C; Zarco L Biomedica; 2020 Mar; 40(1):129-136. PubMed ID: 32220169 [TBL] [Abstract][Full Text] [Related]
11. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Sipe JC Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859 [TBL] [Abstract][Full Text] [Related]
12. Evaluating response to disease-modifying therapy in relapsing multiple sclerosis. Freedman MS; Abdoli M Expert Rev Neurother; 2015 Apr; 15(4):407-23. PubMed ID: 25764966 [TBL] [Abstract][Full Text] [Related]
13. [Personality features in multiple sclerosis patients with a relapsing-remitting course of the disease]. Papuć E; Pawłowska B Psychiatr Pol; 2005; 39(4):669-78. PubMed ID: 16237972 [TBL] [Abstract][Full Text] [Related]
14. The psychosocial effect of multiple sclerosis: the impact of relapses. Halper J J Neurol Sci; 2007 May; 256 Suppl 1():S34-8. PubMed ID: 17350047 [TBL] [Abstract][Full Text] [Related]
15. Adherence to biologic DMARD therapies in rheumatoid arthritis. Koncz T; Pentek M; Brodszky V; Ersek K; Orlewska E; Gulacsi L Expert Opin Biol Ther; 2010 Sep; 10(9):1367-78. PubMed ID: 20681888 [TBL] [Abstract][Full Text] [Related]
17. Exacerbation history is associated with medication and appointment adherence in MS. Hancock LM; Bruce JM; Lynch SG J Behav Med; 2011 Oct; 34(5):330-8. PubMed ID: 21259038 [TBL] [Abstract][Full Text] [Related]
18. Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse. Somer E; Golan D; Dishon S; Cuzin-Disegni L; Lavi I; Miller A Mult Scler; 2010 Apr; 16(4):463-71. PubMed ID: 20086022 [TBL] [Abstract][Full Text] [Related]
19. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
20. Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence. Bruce JM; Bruce AS; Lynch S; Thelen J; Lim SL; Smith J; Catley D; Reed DD; Jarmolowicz DP Psychopharmacology (Berl); 2018 Nov; 235(11):3303-3313. PubMed ID: 30244284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]